UA73449A1 - Method for obtaining granules of medical preparation regulating the metabolism processes in myocardium - Google Patents
Method for obtaining granules of medical preparation regulating the metabolism processes in myocardium Download PDFInfo
- Publication number
- UA73449A1 UA73449A1 UA4873019A UA4873019A UA73449A1 UA 73449 A1 UA73449 A1 UA 73449A1 UA 4873019 A UA4873019 A UA 4873019A UA 4873019 A UA4873019 A UA 4873019A UA 73449 A1 UA73449 A1 UA 73449A1
- Authority
- UA
- Ukraine
- Prior art keywords
- myocardium
- acetylphthalylcellulose
- solution
- degree
- juices
- Prior art date
Links
- 239000008187 granular material Substances 0.000 title claims abstract description 5
- 210000004165 myocardium Anatomy 0.000 title claims abstract 4
- 230000004060 metabolic process Effects 0.000 title claims abstract 3
- 238000000034 method Methods 0.000 title claims description 4
- 230000001105 regulatory effect Effects 0.000 title abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 4
- 239000000843 powder Substances 0.000 claims abstract description 4
- 235000002767 Daucus carota Nutrition 0.000 claims abstract description 3
- 244000000626 Daucus carota Species 0.000 claims abstract description 3
- 244000300264 Spinacia oleracea Species 0.000 claims abstract description 3
- 235000009337 Spinacia oleracea Nutrition 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims abstract 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000012467 final product Substances 0.000 claims abstract 2
- 239000011591 potassium Substances 0.000 claims abstract 2
- 229910052700 potassium Inorganic materials 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 229960000259 magnesium asparaginate Drugs 0.000 claims description 2
- ZHYLJCKTXNWNPJ-CEOVSRFSSA-L magnesium;(2s)-2,4-diamino-4-oxobutanoate Chemical compound [Mg+2].[O-]C(=O)[C@@H](N)CC(N)=O.[O-]C(=O)[C@@H](N)CC(N)=O ZHYLJCKTXNWNPJ-CEOVSRFSSA-L 0.000 claims description 2
- 229960003193 potassium asparaginate Drugs 0.000 claims description 2
- 240000000073 Achillea millefolium Species 0.000 claims 1
- 235000007754 Achillea millefolium Nutrition 0.000 claims 1
- 244000025254 Cannabis sativa Species 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 235000013311 vegetables Nutrition 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 1
- 235000002974 Sisymbrium officinale Nutrition 0.000 abstract 1
- 240000007807 Sisymbrium officinale Species 0.000 abstract 1
- 239000011777 magnesium Substances 0.000 abstract 1
- 229910052749 magnesium Inorganic materials 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 6
- 206010003119 arrhythmia Diseases 0.000 description 4
- 230000006793 arrhythmia Effects 0.000 description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002600 fibrillogenic effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- KLISBMUDTJHGSP-AIDJSRAFSA-K magnesium;potassium;(2s)-2-amino-4-hydroxy-4-oxobutanoate;2-amino-4-hydroxy-4-oxobutanoate Chemical compound [Mg+2].[K+].[O-]C(=O)C(N)CC(O)=O.[O-]C(=O)C(N)CC(O)=O.[O-]C(=O)[C@@H](N)CC(O)=O KLISBMUDTJHGSP-AIDJSRAFSA-K 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- NRFNNNBFDIFBLS-DKWTVANSSA-M potassium;(2s)-2,4-diamino-4-oxobutanoate Chemical compound [K+].[O-]C(=O)[C@@H](N)CC(N)=O NRFNNNBFDIFBLS-DKWTVANSSA-M 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
17,5г полученньїх сухих соков желтушника, 37,9г моркови, З0,5г шпината, З,Ог аспарагината калия, З,0г аспарагината магния увлажняют 0,190-ньмм раствором АФЦ в количестве 1095 от веса порошков, протирают через сито с диаметром отверстий 2мм ГОСТ 4403-67.17.5g of the obtained dry juices of the yolk, 37.9g of carrot, 30.5g of spinach, 3.0g of potassium asparaginate, 3.0g of magnesium asparaginate are moistened with a 0.190-nm solution of AFC in the amount of 1095 g by weight of powders, rubbed through a sieve with a hole diameter of 2mm GOST 4403-67.
Полученнье грануль! сушат при температуре 40-52,Getting pellets! dried at a temperature of 40-52,
Готовьій продукт представляет собой грануль! желтого цвета, приятного запаха.The finished product is a granule! yellow color, pleasant smell.
Пример Мо2. Осуществляеєется аналогично примеру Мої, количество зтилового спирта для осаждения белковьїх веществ необходимо взять равньї/м 1/4 части фильтра.An example of Mo2. It is carried out similarly to my example, the amount of ethyl alcohol for the precipitation of protein substances must be taken equal to 1/4 part of the filter.
Пример Мо3. Осуществляется аналогично примеру Мої, но температурньйй режим сушки 55-60 С и их протирают через сито с диаметром отверстий Змм.An example of Mo3. It is carried out similarly to the example of Mine, but the drying temperature is 55-60 C and they are wiped through a sieve with a hole diameter of Zmm.
Пример Мо4. Антиаритмическую активность заявляемого обьекта изучали на моделях хлоркальцевой аритмии, которую вьізьвали внутривенньм введением 1095 раствора кальция хлорида в дозе 200мг/кг.An example of Mo4. The antiarrhythmic activity of the proposed object was studied on models of chlorcalcic arrhythmia, which was induced by intravenous administration of 1095 calcium chloride solution at a dose of 200mg/kg.
Злектрокардиограмму снимали во ІІ стандартном отведении. Критериями зффективности бьіли признаки купирования аритмии и продолжительность жизни животньх.The electrocardiogram was recorded in the II standard lead. The criteria for effectiveness were the symptoms of stopping the arrhythmia and the life expectancy of the animals.
Заявляемьй препарат вводили внутрижелудочно за 40 мин до иньекции кальция хлорида в дозе 11010 во г/кг.The claimed drug was administered intragastrically 40 minutes before the injection of calcium chloride in a dose of 11010 g/kg.
Результать! опьітов обрабатьвали с помощью методов вариационной статистики. Бьіло поставлено 40 зкспериментов. Наблюдение проводили в течение 6бО мин. У интактньїх животньїх на злектрокардиограмме аритмия отсутствовала на протяжение всего 10 периода наблюдения. В контрольной (не леченной) группе животньїх нарушение ритма наступало сразу после введения СаСіо и через 2-2,5 мин заканчивалось 100905 гибелью. В группе животньх с 15 предварительньім введением препарата заявляемого обьекта после введенияThe result! opiates were processed using the methods of variational statistics. White put 40 experiments. The observation was carried out for 6 minutes. In intact animals, there was no arrhythmia on the electrocardiogram for only 10 observation periods. In the control (untreated) group of animals, the rhythm disturbance occurred immediately after the introduction of CaSio and after 2-2.5 minutes ended with 100905 death. In the group of animals with 15 preliminary administration of the drug of the claimed object after administration
Сасі» появлялась аритмия, но фибрилляция, как правило не наступала, в отличие от контрольной (не леченнье животнье) и группь! с предварительньмм введением аспаркама. Нормальньй сердечньій ритм восстанавливался у 40-4595 животньх. «-Sasi" had an arrhythmia, but fibrillation, as a rule, did not occur, unlike the control (non-treated animal) and groups! with the preliminary introduction of asparkam. Normal heart rhythm was restored in 40-4595 animals. "-
Препарат, полученньій заявляемь!м способом, практически нетоксичен, І Осо - 11,3 г/кг. «The drug obtained by the claimed method is practically non-toxic, I Oso - 11.3 g/kg. "
Положительньій зффект заключаєется в повьнішениий зффективности полученного средства. (о) « « (зе) у . и? -і (95) щ» щ» іЧе)The positive effect consists in the improvement of the effectiveness of the obtained means. (o) « « (ze) in . and? -i (95) sh» sh» iChe)
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA4873019A UA73449A1 (en) | 1990-09-10 | 1990-09-10 | Method for obtaining granules of medical preparation regulating the metabolism processes in myocardium |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA4873019A UA73449A1 (en) | 1990-09-10 | 1990-09-10 | Method for obtaining granules of medical preparation regulating the metabolism processes in myocardium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA73449A1 true UA73449A1 (en) | 2005-07-15 |
Family
ID=34882510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA4873019A UA73449A1 (en) | 1990-09-10 | 1990-09-10 | Method for obtaining granules of medical preparation regulating the metabolism processes in myocardium |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA73449A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2632715C2 (en) * | 2016-03-15 | 2017-10-09 | Общество с ограниченной ответственностью "Фармамед" | Sustained-release pharmaceutical composition containing asparaginates |
| RU2632713C2 (en) * | 2016-02-18 | 2017-10-09 | Общество с ограниченной ответственностью "Фармамед" | Delayed release pharmaceutical composition containing asparaginates |
-
1990
- 1990-09-10 UA UA4873019A patent/UA73449A1/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2632713C2 (en) * | 2016-02-18 | 2017-10-09 | Общество с ограниченной ответственностью "Фармамед" | Delayed release pharmaceutical composition containing asparaginates |
| RU2632715C2 (en) * | 2016-03-15 | 2017-10-09 | Общество с ограниченной ответственностью "Фармамед" | Sustained-release pharmaceutical composition containing asparaginates |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US2786014A (en) | Platelet preservation | |
| James | Oxalate toxicosis | |
| DE2838308A1 (en) | METHOD OF MANUFACTURING PILLS FOR ORAL TRACKING IN RUMER | |
| Desikachar et al. | Role of inhibitors in soybean | |
| JP6409151B1 (en) | Method for producing oral composition and oral composition | |
| UA73449A1 (en) | Method for obtaining granules of medical preparation regulating the metabolism processes in myocardium | |
| CN1683345A (en) | Acid salt for synergistic medicine of chuanqiongzine and its preparing method | |
| DE3134591A1 (en) | NEW MEDICINE PREPARATIONS FOR GLYCOSIDE HYDROLASE INHIBITORS | |
| US2146083A (en) | Preparation for the treatment of diseases in fowl and animals | |
| WO2000048613A1 (en) | Method of treatment of equine disease | |
| US3291689A (en) | Malic acid and arginine composition for treating hepatic dysfunction | |
| US7767712B2 (en) | Storage-stable aqueous composition comprising a magnesium compound and L-carnitine | |
| US3070508A (en) | Method for rendering nicotinamide palatable | |
| de Pasqualini | The effect of ascorbic acid on hemorrhagic shock in the guinea pig | |
| JP2731051B2 (en) | Pharmaceutical composition for equine virus infection and method of treating the same | |
| DE2611979A1 (en) | Antiflatulence and diarrhoea compsn. for pigs and cattle - comprising specified plants, linseed, lactic acid and cattle salt | |
| US3888980A (en) | Antimicrobial compounds of 2', 5'+0 substituted nitroanilides of substituted nitrosalicylic acid for quadruped animals | |
| RU2268040C2 (en) | Preparation for treating diarrhea in youngsters of farm animals and method for its application | |
| RU2052266C1 (en) | Method of cow hepatosis treatment | |
| RU2308188C2 (en) | Application of feedstuff treated with "hymizyme" polyenzymatic preparation in case of intoxication with heavy metals in animals and hens | |
| US3754082A (en) | Process and composition for botfly larvae eliminination | |
| DE3880498T2 (en) | USE OF 5-AMINOSALICYL ACID (5-ASA) FOR PRODUCING A MEDICINAL PREPARATION FOR USE IN A REPERFUSION TREATMENT. | |
| RU2141317C1 (en) | Preparation antidiarrhin for prophylaxis and treatment of agriculture animals with diarrhea gastroenteric sicknesses and method of its using | |
| US2768113A (en) | Therapeutic composition of procaine and adrenaline precursor | |
| RU2251267C1 (en) | Insecticidal composition for controlling gadffly's larvae |